
GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems. The …

GlaxoSmithKline is looking to make more than £7 billion by selling off its ageing portfolio of established drugs. This is …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader

